日化薬 reported cumulative ordinary profit of ¥14.8 billion for the first half of the fiscal year, up 36.6% year on year, and raised its full-year forecast from ¥27.0 billion to ¥27.9 billion. Second-half profit is expected to be ¥13.0 billion, down 10.6% year on year.
日本化薬 reported in its earnings summary that consolidated ordinary profit for the cumulative second quarter (April–September) of the fiscal year ending March 2027 rose to ¥14.8 billion, up 36.6% year on year. It also raised its full-year ordinary profit forecast by 3.3%, from ¥27.0 billion to ¥27.9 billion, increased the profit growth rate from 6.0% to 9.5%, and further raised its record-high profit forecast.
However, based on the latest first-half results and full-year plan, second-half (October–March) ordinary profit is estimated at ¥13.0 billion, down 10.6% year on year.
For July–September, ordinary profit was ¥7.42 billion, up 9.6% year on year. Sorry, the original figure is ¥7.42 billion, up 9.6% year on year, and the operating margin on sales improved from 10.6% to 12.2%. These figures were also released based on the earnings summary.
The announcement included revisions intended to offset the gap between first-half results and the full-year plan, and is expected to affect full-year net profit and earnings per share.